Low-Dose Remimazolam Changed Six-Hour Nausea but Not the Twenty-Four-Hour Endpoint

The assessment window can determine whether an apparent antiemetic benefit is present.

Study findings

In the 108-patient trial, all participants received ramosetron and dexamethasone during sevoflurane anesthesia. Additional low-dose remimazolam did not clearly reduce the twenty-four-hour nausea-and-vomiting endpoint. Nausea at six hours and dizziness in the recovery unit were less frequent in the remimazolam group.

What limits the conclusion

The study involved women aged nineteen to sixty-five and one tested infusion strategy. Selected early secondary differences should not replace the main later result. Other antiemetic treatment was shared rather than absent.

Implications for case review

Specify time, endpoint and background regimen before describing efficacy. The source does not show that remimazolam alone prevents postoperative vomiting or improves every recovery measure. Individual causation requires the actual medication package, symptom timing and alternative explanations rather than a general antiemetic label.

Source and related reading

Source: PMC12403298, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.

Related: Gastroscopy Dose-Finding Still Required Propofol Rescue in Four of Twenty-Two Patients.